Effectiveness of Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy in Heart Failure

Heart Failure Clinics

Volumn 9, Issue 1, 2013, Pages 59-77

  Freeman, James V ^a   Masoudi, Frederick A ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Cardiac resynchronization therapy; CRT; ICD; Implantable cardioverter defibrillator; Sudden cardiac death

Indexed keywords

ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; SPIRONOLACTONE;

CARDIAC RESYNCHRONIZATION THERAPY; HEART DEATH; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RIGHT BUNDLE BRANCH BLOCK; HEART VENTRICLE ARRHYTHMIA; HOSPITALIZATION; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; ISCHEMIC CARDIOMYOPATHY; KIDNEY FAILURE; PRACTICE GUIDELINE; PRIMARY PREVENTION; REVIEW; SECONDARY PREVENTION; SUDDEN DEATH; SURVIVAL;

AGE FACTORS; AGED; CARDIAC RESYNCHRONIZATION THERAPY; COMPARATIVE EFFECTIVENESS RESEARCH; DEFIBRILLATORS, IMPLANTABLE; DISEASE MANAGEMENT; FEMALE; HEART FAILURE; HUMANS; MALE; META-ANALYSIS AS TOPIC; MIDDLE AGED; OBSERVATION; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SECONDARY PREVENTION; SEVERITY OF ILLNESS INDEX; SEX FACTORS; SURVIVAL RATE;

EID: 84869504740     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2012.09.006     Document Type: Review

References (76)

1. Lloyd-Jones D., Adams R.J., Brown T.M., et al. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 2010, 121(7):e46-e215.
2. McMurray J.J., Petrie M.C., Murdoch D.R., et al. Clinical epidemiology of heart failure: public and private health burden. Eur Heart J 1998, 19(Suppl P):P9-P16.
3. Kannel W.B., Wilson P.W., D'Agostino R.B., et al. Sudden coronary death in women. Am Heart J 1998, 136(2):205-212.
4. Mosterd A., Cost B., Hoes A.W., et al. The prognosis of heart failure in the general population: The Rotterdam Study. Eur Heart J 2001, 22(15):1318-1327.
5. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991, 325(5):293-302.
6. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N Engl J Med 1992, 327(10):685-691.
7. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999, 353(9169):2001-2007.
8. Pfeffer M.A., Braunwald E., Moye L.A., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992, 327(10):669-677.
9. Moss A.J., Hall W.J., Cannom D.S., et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996, 335(26):1933-1940.
10. Moss A.J., Fadl Y., Zareba W., et al. Survival benefit with an implanted defibrillator in relation to mortality risk in chronic coronary heart disease. Am J Cardiol 2001, 88(5):516-520.
11. Moss A.J., Zareba W., Hall W.J., et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002, 346(12):877-883.
12. Greenberg H., Case R.B., Moss A.J., et al. Analysis of mortality events in the Multicenter Automatic Defibrillator Implantation Trial (MADIT-II). J Am Coll Cardiol 2004, 43(8):1459-1465.
13. Buxton A.E., Lee K.L., Fisher J.D., et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 1999, 341(25):1882-1890.
14. Bardy G.H., Lee K.L., Mark D.B., et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005, 352(3):225-237.
15. Bristow M.R., Saxon L.A., Boehmer J., et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004, 350(21):2140-2150.
16. Kuck K.H., Cappato R., Siebels J., et al. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation 2000, 102(7):748-754.
17. Connolly S.J., Gent M., Roberts R.S., et al. Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 2000, 101(11):1297-1302.
18. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. N Engl J Med 1997, 337(22):1576-1583.
19. Moss A.J., Hall W.J., Cannom D.S., et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 2009, 361(14):1329-1338.
20. Tang A.S., Wells G.A., Talajic M., et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med 2010, 363(25):2385-2395.
21. Cleland J.G., Daubert J.C., Erdmann E., et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005, 352(15):1539-1549.
22. Saxon L.A., Bristow M.R., Boehmer J., et al. Predictors of sudden cardiac death and appropriate shock in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Trial. Circulation 2006, 114(25):2766-2772.
23. Cleland J.G., Daubert J.C., Erdmann E., et al. Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the CArdiac REsynchronization-Heart Failure (CARE-HF) trial extension phase]. Eur Heart J 2006, 27(16):1928-1932.
24. Abraham W.T., Fisher W.G., Smith A.L., et al. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002, 346(24):1845-1853.
25. St John Sutton M.G., Plappert T., Abraham W.T., et al. Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure. Circulation 2003, 107(15):1985-1990.
26. Young J.B., Abraham W.T., Smith A.L., et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial. JAMA 2003, 289(20):2685-2694.
27. Cazeau S., Leclercq C., Lavergne T., et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 2001, 344(12):873-880.
28. Leclercq C., Walker S., Linde C., et al. Comparative effects of permanent biventricular and right-univentricular pacing in heart failure patients with chronic atrial fibrillation. Eur Heart J 2002, 23(22):1780-1787.
29. Linde C., Leclercq C., Rex S., et al. Long-term benefits of biventricular pacing in congestive heart failure: results from the MUltisite STimulation in cardiomyopathy (MUSTIC) study. J Am Coll Cardiol 2002, 40(1):111-118.
30. Auricchio A., Stellbrink C., Sack S., et al. Long-term clinical effect of hemodynamically optimized cardiac resynchronization therapy in patients with heart failure and ventricular conduction delay. J Am Coll Cardiol 2002, 39(12):2026-2033.
31. Higgins S.L., Hummel J.D., Niazi I.K., et al. Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias. J Am Coll Cardiol 2003, 42(8):1454-1459.
32. Kindermann M., Hennen B., Jung J., et al. Biventricular versus conventional right ventricular stimulation for patients with standard pacing indication and left ventricular dysfunction: the Homburg Biventricular Pacing Evaluation (HOBIPACE). J Am Coll Cardiol 2006, 47(10):1927-1937.
33. Linde C., Abraham W.T., Gold M.R., et al. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol 2008, 52(23):1834-1843.
34. Zipes D.P., Camm A.J., Borggrefe M., et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death-executive summary: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in Collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Eur Heart J 2006, 27(17):2099-2140.
35. Epstein A.E., DiMarco J.P., Ellenbogen K.A., et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008, 117(21):e350-e408.
36. Mark D.B., Anstrom K.J., Sun J.L., et al. Quality of life with defibrillator therapy or amiodarone in heart failure. N Engl J Med 2008, 359(10):999-1008.
37. Theuns D.A., Smith T., Hunink M.G., et al. Effectiveness of prophylactic implantation of cardioverter-defibrillators without cardiac resynchronization therapy in patients with ischaemic or non-ischaemic heart disease: a systematic review and meta-analysis. Europace 2010, 12(11):1564-1570.
38. Hohnloser S.H., Kuck K.H., Dorian P., et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 2004, 351(24):2481-2488.
39. Steinbeck G., Andresen D., Seidl K., et al. Defibrillator implantation early after myocardial infarction. N Engl J Med 2009, 361(15):1427-1436.
40. Al-Khatib S.M., Hellkamp A., Curtis J., et al. Non-evidence-based ICD implantations in the United States. JAMA 2011, 305(1):43-49.
41. Dorian P., Hohnloser S.H., Thorpe K.E., et al. Mechanisms underlying the lack of effect of implantable cardioverter-defibrillator therapy on mortality in high-risk patients with recent myocardial infarction: insights from the defibrillation in acute myocardial infarction trial (DINAMIT). Circulation 2010, 122(25):2645-2652.
42. Sweeney M.O. The contradiction of appropriate shocks in primary prevention ICDs: increasing and decreasing the risk of death. Circulation 2010, 122(25):2638-2641.
43. Knight BP. Implantable cardioverter-defibrillators: clinical trials of primary prevention of sudden cardiac death. UpToDate Online 18.3. 2009. Available at: Accessed December 14, 2010. http://www.uptodate.com.
44. Strickberger S.A., Hummel J.D., Bartlett T.G., et al. Amiodarone versus implantable cardioverter-defibrillator: randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia-AMIOVIRT. J Am Coll Cardiol 2003, 41(10):1707-1712.
45. Bigger J.T. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. N Engl J Med 1997, 337(22):1569-1575.
46. Bansch D., Antz M., Boczor S., et al. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT). Circulation 2002, 105(12):1453-1458.
47. Kadish A., Dyer A., Daubert J.P., et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004, 350(21):2151-2158.
48. Desai A.S., Fang J.C., Maisel W.H., et al. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials. JAMA 2004, 292(23):2874-2879.
49. Causes of death in the Antiarrhythmics Versus Implantable Defibrillators (AVID) Trial. J Am Coll Cardiol 1999, 34(5):1552-1559.
50. Lee D.S., Green L.D., Liu P.P., et al. Effectiveness of implantable defibrillators for preventing arrhythmic events and death: a meta-analysis. J Am Coll Cardiol 2003, 41(9):1573-1582.
51. Saba S., Atiga W.L., Barrington W., et al. Selected patients listed for cardiac transplantation may benefit from defibrillator implantation regardless of an established indication. J Heart Lung Transplant 2003, 22(4):411-418.
52. Ghanbari H., Dalloul G., Hasan R., et al. Effectiveness of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death in women with advanced heart failure: a meta-analysis of randomized controlled trials. Arch Intern Med 2009, 169(16):1500-1506.
53. Peterson P.N., Daugherty S.L., Wang Y., et al. Gender differences in procedure-related adverse events in patients receiving implantable cardioverter-defibrillator therapy. Circulation 2009, 119(8):1078-1084.
54. Santangeli P., Di Biase L., Dello Russo A., et al. Meta-analysis: age and effectiveness of prophylactic implantable cardioverter-defibrillators. Ann Intern Med 2010, 153(9):592-599.
55. Hernandez A.F., Fonarow G.C., Hammill B.G., et al. Clinical effectiveness of implantable cardioverter-defibrillators among Medicare beneficiaries with heart failure. Circ Heart Fail 2010, 3(1):7-13.
56. Chan P.S., Nallamothu B.K., Spertus J.A., et al. Impact of age and medical comorbidity on the effectiveness of implantable cardioverter-defibrillators for primary prevention. Circ Cardiovasc Qual Outcomes 2009, 2(1):16-24.
57. Epstein A.E., Kay G.N., Plumb V.J., et al. Implantable cardioverter-defibrillator prescription in the elderly. Heart Rhythm 2009, 6(8):1136-1143.
58. Goldenberg I., Moss A.J., McNitt S., et al. Relations among renal function, risk of sudden cardiac death, and benefit of the implanted cardiac defibrillator in patients with ischemic left ventricular dysfunction. Am J Cardiol 2006, 98(4):485-490.
59. Aggarwal A., Wang Y., Rumsfeld J.S., et al. Clinical characteristics and in-hospital outcome of patients with end-stage renal disease on dialysis referred for implantable cardioverter-defibrillator implantation. Heart Rhythm 2009, 6(11):1565-1571.
60. Freeman J.V., Wang Y., Curtis J.P., et al. The relation between hospital procedure volume and complications of cardioverter-defibrillator implantation from the implantable cardioverter-defibrillator registry. J Am Coll Cardiol 2010, 56(14):1133-1139.
61. Kuhlkamp V., Dornberger V., Mewis C., et al. Clinical experience with the new detection algorithms for atrial fibrillation of a defibrillator with dual chamber sensing and pacing. J Cardiovasc Electrophysiol 1999, 10(7):905-915.
62. Deisenhofer I., Kolb C., Ndrepepa G., et al. Do current dual chamber cardioverter defibrillators have advantages over conventional single chamber cardioverter defibrillators in reducing inappropriate therapies? A randomized, prospective study. J Cardiovasc Electrophysiol 2001, 12(2):134-142.
63. Theuns D.A., Klootwijk A.P., Goedhart D.M., et al. Prevention of inappropriate therapy in implantable cardioverter-defibrillators: results of a prospective, randomized study of tachyarrhythmia detection algorithms. J Am Coll Cardiol 2004, 44(12):2362-2367.
64. Dorian P., Philippon F., Thibault B., et al. Randomized controlled study of detection enhancements versus rate-only detection to prevent inappropriate therapy in a dual-chamber implantable cardioverter-defibrillator. Heart Rhythm 2004, 1(5):540-547.
65. Bansch D., Steffgen F., Gronefeld G., et al. The 1+1 trial: a prospective trial of a dual- versus a single-chamber implantable defibrillator in patients with slow ventricular tachycardias. Circulation 2004, 110(9):1022-1029.
66. Friedman P.A., McClelland R.L., Bamlet W.R., et al. Dual-chamber versus single-chamber detection enhancements for implantable defibrillator rhythm diagnosis: the detect supraventricular tachycardia study. Circulation 2006, 113(25):2871-2879.
67. Theuns D.A., Rivero-Ayerza M., Boersma E., et al. Prevention of inappropriate therapy in implantable defibrillators: a meta-analysis of clinical trials comparing single-chamber and dual-chamber arrhythmia discrimination algorithms. Int J Cardiol 2008, 125(3):352-357.
68. Curtis J.P., Luebbert J.J., Wang Y., et al. Association of physician certification and outcomes among patients receiving an implantable cardioverter-defibrillator. JAMA 2009, 301(16):1661-1670.
69. Lam S.K., Owen A. Combined resynchronisation and implantable defibrillator therapy in left ventricular dysfunction: Bayesian network meta-analysis of randomised controlled trials. BMJ 2007, 335(7626):925.
70. Anand I.S., Carson P., Galle E., et al. Cardiac resynchronization therapy reduces the risk of hospitalizations in patients with advanced heart failure: results from the Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) trial. Circulation 2009, 119(7):969-977.
71. McAlister F.A., Ezekowitz J., Hooton N., et al. Cardiac resynchronization therapy for patients with left ventricular systolic dysfunction: a systematic review. JAMA 2007, 297(22):2502-2514.
72. Fein A.S., Wang Y., Curtis J.P., et al. Prevalence and predictors of off-label use of cardiac resynchronization therapy in patients enrolled in the National Cardiovascular Data Registry Implantable Cardiac-Defibrillator Registry. J Am Coll Cardiol 2010, 56(10):766-773.
73. Lindenfeld J., Feldman A.M., Saxon L., et al. Effects of cardiac resynchronization therapy with or without a defibrillator on survival and hospitalizations in patients with New York Heart Association class IV heart failure. Circulation 2007, 115(2):204-212.
74. Germany R.E., Ripley T.L. Controversies in cardiac resynchronization therapy: do sex differences in response exist?. Curr Heart Fail Rep 2011, 8(1):59-64.
75. Bilchick K.C., Kamath S., DiMarco J.P., et al. Bundle-branch block morphology and other predictors of outcome after cardiac resynchronization therapy in Medicare patients. Circulation 2010, 122(20):2022-2030.
76. Jessup M., Abraham W.T., Casey D.E., et al. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009, 119(14):1977-2016.